Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07600476
PHASE1

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Sponsor: Kupando GmbH

View on ClinicalTrials.gov

Summary

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2026-07-03

Completion Date

2028-12

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

DRUG

KUP-101A

Intravenous infusion of KUP-101A

Locations (4)

Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie

Munich, Bavaria, Germany

Universitätsklinikum Würzburg

Würzburg, Bavaria, Germany

Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie

Marburg, Hesse, Germany

Fachklinik Hornheide

Münster, North Rhine-Westphalia, Germany